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In this review, we discuss how changes in the intragraft microenvironment serve to pro-
mote or sustain the development of chronic allograft rejection. We propose two key
elements within the microenvironment that contribute to the rejection process.The ﬁrst is
endothelial cell proliferation and angiogenesis that serve to create abnormal microvas-
cular blood ﬂow patterns as well as local tissue hypoxia, and precedes endothelial-to-
mesenchymal transition. The second is the overexpression of local cytokines and growth
factors that serve to sustain inﬂammation and, in turn, function to promote a leukocyte-
induced angiogenesis reaction. Central to both events is overexpression of vascular
endothelial growth factor (VEGF), which is both pro-inﬂammatory and pro-angiogenic, and
thus drives progression of the chronic rejection microenvironment. In our discussion, we
focus on how inﬂammation results in angiogenesis and how leukocyte-induced angiogen-
esis is pathological. We also discuss how VEGF is a master control factor that fosters
the development of the chronic rejection microenvironment. Overall, this review provides
insight into the intragraft microenvironment as an important paradigm for future direction
in the ﬁeld.
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GENERAL OVERVIEW
In an endothelial cell (EC)-based model, the initiation of inﬂam-
mation within an allograft results from the activation of donor
ECs responding to pro-inﬂammatory cytokines released from res-
ident macrophages in response to hypoxia (Cotran, 1994; Briscoe
et al., 1998; Denton et al., 2000; Pober and Sessa, 2007; Ingulli
et al., 2009). Graft EC also respond to cytokines and growth
factors produced in association with alloimmune cellular and
humoral targeting of the graft (Pober et al., 1996; Valujskikh and
Heeger, 2003; Zhang and Reed, 2009; Halloran et al., 2010; Sis
and Halloran, 2010), as well as by factors produced by inﬁltrat-
ing mononuclear cells that are characteristic of chronic rejection
(Libby andPober, 2001). The induced expression of adhesionmol-
ecules and chemokines by donor EC results in the recruitment of
leukocytes into the graft, whereas the expression of MHC class I
and II molecules on donor EC is critical for the local presenta-
tion of alloantigen to inﬁltrating effector/memory lymphocytes
(Briscoe and Sayegh, 2002; Kreisel et al., 2002; Pober and Sessa,
2007). These events set the stage for an intragraft microenviron-
ment that sustains donor-directed alloimmune inﬂammation and
the development of chronic rejection.
In this review, we focus on how the integrity of the vascular
endothelium is critical for a microenvironment that sustains allo-
graft function. In vascularized solid organ allografts, such as the
kidney, early ischemia–reperfusion results in profound injury to
the microvasculature (Bishop et al., 1989; Vos and Briscoe, 2002;
Woywodt et al., 2003; Reinders et al., 2006; Aydin et al., 2007;
Contreras and Briscoe, 2007; Rabelink et al., 2007; Mayer, 2011).
Furthermore, the degree of injury and microvascular EC loss at
early times post transplantation can be predictive of long-term
graft survival (Bishop et al., 1989; Choi et al., 2000; Fine and Nor-
man, 2008; Mayer, 2011; Steegh et al., 2011). Indeed, it is reported
that the sequential loss of peritubular capillaries, starting as early
as 3months post renal transplantation predicts the development
of interstitial ﬁbrosis and tubular atrophy (IFTA) and later chronic
rejection (Steegh et al., 2011). It is proposed that the loss of the
intrarenal microvasculature results in impaired delivery of oxygen
and nutrients to the renal tubules, which in turn contributes to
local tissue ischemia, tubular dropout, and cell death (Kang et al.,
2002; Reinders et al., 2006; Contreras and Briscoe, 2007; Rabelink
et al., 2007; Fine and Norman, 2008; Mayer, 2011). Thus, the ini-
tial loss of microvessels/peritubular capillaries may be a primary
factor in the development of ﬁbrosis and chronic renal disease
(Kang et al., 2002; Reinders and Briscoe, 2002; Contreras and
Briscoe, 2007; Mayer, 2011). Pharmacologic therapy which can
protect microvascular integrity at early times post transplantation
has potential to improve long-term graft survival (Johnson et al.,
2006; Nakao et al., 2006; Aydin et al., 2007; Rabelink et al., 2007;
Briscoe and Pal, 2008; Leonard et al., 2008; Hanto et al., 2010).
If early protection and repair is not accomplished, then ongoing
local ischemia will result in cellular atrophy, and chronic allograft
disease will be inevitable.
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However, it is underappreciated that inﬂammatory inﬁltrates
also cause EC proliferation, a process called leukocyte-induced
angiogenesis (Auerbach and Sidky, 1979; Cotran, 1994). In addi-
tion, the binding of alloantibodies to the graft vascular endothe-
lium can result in EC activation and a proliferative response
(Zhang and Reed, 2009). As will be discussed below, this abnor-
mal or pathological angiogenesis response may be associated with
local tissue hypoxia, and thus precedes later hypoxic tissue injury
(Babu et al., 2007; Contreras and Briscoe, 2007; Goel et al., 2011).
If EC proliferation occurs at later times post transplantation in
association with pericyte loss, microvessels become disorganized
and endothelial-to-mesenchymal transition (EndMT) may occur.
This results in collagen deposition and tissue ﬁbrosis (Schor et al.,
1995; Humphreys et al., 2010; Medici et al., 2010). Central to all
these events is the expression of vascular endothelial growth fac-
tor (VEGF), which is both pro-angiogenic and pro-inﬂammatory,
and thus drives progression of the chronic rejection microenvi-
ronment (Reinders et al., 2006). Here, we discuss a new paradigm,
whereby local tissue hypoxia and overexpressed intragraft VEGF
are key features of a microenvironment that determine the devel-
opment of chronic rejection. Cartoons illustrating this paradigm
are shown in Figures 1 and 2.
MICROVASCULAR PATTERNING AND THE INTRAGRAFT
MICROENVIRONMENT
Angiogenesis, the generation of new blood vessels from pre-
existing ones, is a complex process involving the degradation of
the vascular basement membrane and surrounding extracellular
matrix as well as EC proliferation and migration (Cotran, 1994;
Folkman, 1995a,b; Brown et al., 1997; Carmeliet and Jain, 2000;
Ferrara and Kerbel, 2005; Goel et al., 2011). The creation of new
blood vessels is critical for normal organ growth and development
and it is a requirement for normal wound healing and tissue repair
(Cotran, 1994; Majno, 1998). In all of these biological conditions,
angiogenesis is tightly regulated in a tissue speciﬁc manner, such
that the microvascular bed provides tissues with their nutritive
and oxygen demands in a manner that is sufﬁcient for normal
physiological processes. However, angiogenesis is also character-
istic of many disease states, and is well-established to occur in
association with cell-mediated immune responses (Cotran, 1994)
and chronic inﬂammatory diseases (Folkman andBrem,1992; Fer-
rara and Alitalo, 1999; Ezaki et al., 2001), notably inﬂammatory
bowel disease (Kanazawa et al., 2001), arthritis (Walsh and Pear-
son, 2001), chronic asthma (Detoraki et al., 2010), and chronic
allograft rejection (Tanaka et al., 1994;Moulton et al., 1999; Rein-
FIGURE 1 | Cartoon illustrating the interplay between alloimmunity and
the intragraft microvasculature. (A) Following transplantation, alloimmune
inﬂammatory responses target the graft vascular endothelium resulting in the
destruction of microvessels, which in turn leads to local hypoxia and tissue
injury. (B) Alloimmune inﬂammatory responses may also stimulate
endothelial cell proliferation and promote leukocyte-induced angiogenesis
within allografts. The local delivery of the pro-inﬂammatory and
pro-angiogenic factor vascular endothelial growth factor (VEGF) is central to
this response. Pathological leukocyte-induced angiogenesis results in the
formation of abnormal networks of capillaries that lead to chaotic blood ﬂow
patterns and paradoxically results in local hypoxia. Thus, local tissue hypoxia
is the end result of acute events and direct targeting of the graft endothelial
cells (A) as well as inﬂammation and the associated leukocyte-induced
angiogenesis (B).
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FIGURE 2 | Cartoon illustrating a mechanism of tissue fibrosis associated
with allograft rejection. During inﬂammation, pathological angiogenesis,
and/or local hypoxia can lead to pericyte loss. Under normal conditions
homeostatic repair occurs under the inﬂuence of protective growth and
survival factors. In contrast, when the inﬂammatory microenvironment is
sustained, the loss of pericytes serves as a precedent for
endothelial-to-mesenchymal transition (EndMT), where endothelial cells
become denuded from their basement membrane and migrate along with
pericytes into the surrounding tissue. Although still under debate, it is
reported that the presence of TGFβ, inﬂammatory cytokines, and hypoxia
enables dissociated pericytes and/or endothelial cells to dedifferentiate into
collagen-secreting ﬁbroblasts, which in turn results in ﬁbrosis and scarring.
ders and Briscoe, 2002; Denton et al., 2004; Babu et al., 2007).
In disease processes, the neoangiogenesis response occurs in an
abnormal and disorganized manner. In some chronic disease con-
ditions, such as arthritis and chronic asthma, it canbeuncontrolled
(Walsh and Pearson, 2001; Detoraki et al., 2010). Solid tumors are
a prototype example where angiogenesis can be abnormal and
pathological (Fukumura and Jain, 2007; Jain, 2008; Goel et al.,
2011). In this disease, local tissue hypoxia drives the production of
angiogenesis factors, notably VEGF. This in turn elicits a powerful
neovascular response (Brown et al., 1997; Goel et al., 2011). Since
newly formed vessels are irregular in size with random branching
patterns, the associated blood ﬂow within the entire microvascu-
lar tree becomes abnormal and shunting occurs throughout the
tissue (Jain, 2008; Goel et al., 2011). In this manner, some areas
of the tissue have potential for increased blood ﬂow and have
adequate oxygenation. In contrast, other areas have decreased or
aberrant blood ﬂow which results in local tissue hypoxia. This
latter event further drives the expression of hypoxia-inducible
angiogenesis factors, includingVEGF, such that the cyclical process
is sustained. It is proposed that these events may also occur in
association with chronic kidney disease as well as within kidney
allografts in association with chronic rejection (Choi et al., 2000;
Reinders et al., 2006; Contreras and Briscoe, 2007; Mayer, 2011;
Figure 1). Therefore, local tissue hypoxia may occur as a result of
both initial targeting and loss of microvessels (Figure 1A), or as a
result of leukocyte-induced angiogenesis (Figure 1B).We propose
that once an abnormal pattern of blood vessels develop within
the intragraft microenvironment, it likely serves to elicit local tis-
sue hypoxia as well as to induce VEGF expression, analogous to
that described in tumors (Goel et al., 2011). We hypothesize that
these events sustain inﬂammation and the progression of chronic
rejection.
LEUKOCYTE-INDUCED ANGIOGENESIS: A PATHOLOGICAL
RESPONSE THAT SUSTAINS INTRAGRAFT INJURY
Leukocyte-induced angiogenesis was initially described following
the local injection of spleen cells into the skin of nude mice (Sidky
and Auerbach, 1975; Auerbach and Sidky, 1979). In these original
studies, it was noted that the reaction did not occur following the
injection of syngeneic spleen cells, but it was dose-dependent and
reproducible following the intradermal injection of allogeneic cells
(Auerbach and Sidky, 1979). Subsequently, it was demonstrated
that this leukocyte-induced angiogenesis reactionwasmediated by
CD4+ T lymphocytes (Kaminski and Auerbach, 1988), which we
now understand to be critical for the initiation of the alloimmune
inﬂammatory response (Ingulli et al., 2009). Thus, while not the
intention of these studies, this model clearly indicates that alloac-
tivated leukocytes are potent for the production of angiogenesis
factors. Indeed, it is now known that both monocyte/macrophages
(Koch et al., 1986; Leibovich and Wiseman, 1988; Polverini, 1997)
and activated T cells (Freeman et al., 1995; Melter et al., 2000; Mor
et al., 2004) secrete angiogenesis factors, including VEGF, which is
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a central mediator of the leukocyte-induced reaction (Leibovich
et al., 1987; Giraudo et al., 1998; Reinders et al., 2006). Other
factors including TNF-α (63), TGF-β, and nitric oxide (Wiseman
et al., 1988; Leibovich et al., 1994) may also elicit the response.
Therefore, angiogenesis may result from the local production of
distinct factors, or via cytokine- and cell-mediated responses that
increase local concentrations of VEGF. This interplay between
cell-mediated immune reactions and the local delivery of TGF-β
and VEGF by monocyte/macrophages have resulted in the devel-
opment of paradigms to explain how angiogenesis and ﬁbrosis
are characteristic of chronic inﬂammatory disease states (Cotran,
1994; Brown et al., 1995; Freeman et al., 1995; Sharma et al., 1996;
Inoue et al., 1998; Majno, 1998; Pilmore et al., 1999; Jain et al.,
2000, 2002; Ezaki et al., 2001; Kanazawa et al., 2001; Mannon,
2006; Booth and Bishop, 2010).
In our own studies, we evaluated recipient angiogenesis using
a humanized SCID mouse (huSCID) model of rejection (Moul-
ton et al., 1999). Human foreskin was transplanted onto SCID
mice and was found to engraft after 4–6weeks. Functional ves-
sels and vascular networks within the healed human skin were
derived from both human and mouse EC (Briscoe et al., 1999).
The subsequent adoptive transfer of human peripheral blood
leukocytes into the mouse resulted in human leukocytic inﬁltrates
within the engrafted human skin but not within the adjacent
mouse skin, as evaluated by videomicroscopy and by immuno-
histochemistry (Briscoe et al., 1999; Moulton et al., 1999). After
2–3 days, inﬁltrateswere presentwithin grafts by videomicroscopy,
and by 7 days, inﬁltrates were notable by immunohistochem-
istry; by day 14, cellular inﬁltrates were profound within grafts.
In our analyses, we also found a notable angiogenesis response
that was spatially associated with leukocytic inﬁltrates within
the human skins. The angiogenesis response occurred at early
time points, typically on day 3–5 by videomicroscopy and on
day 7 by immunohistochemistry (Moulton et al., 1999). Notably,
the response preceded the development of marked inﬁltrates,
which were ultimately associated with microvascular destruction.
Therefore, we propose that local tissue hypoxia was not the pri-
mary stimulus for the initiation of the angiogenesis response
within these allografts. Rather, we believe that the angiogen-
esis reaction was initiated by factors produced by inﬁltrating
leukocytes in a similar manner as previously noted by Auer-
bach and Sidky (1979) in their model of leukocyte-induced
angiogenesis.
More recently, Babu et al. (2007) found a similar neovas-
cularization reaction in their analysis of rejecting tracheal allo-
grafts. Although they did not characterize this response in great
detail, their studies illustrated prominent angiogenesis in grafts
on days 4-, 6-, and 8-post transplantation. Similar to our studies
(Moulton et al., 1999; Contreras and Briscoe, 2007), they noted
that it did not persist and completely disappeared by day 10–12
following transplantation in association with fulminant rejec-
tion. However, these authors also evaluated tissue oxygenation
within the graft. Surprisingly, rather than ﬁnding that oxygena-
tion was normal at sites of neovascularization, they observed that
tissue pO2 decreased in day 4–6 allografts when the leukocyte-
induced angiogenesis reaction was prominent (Babu et al., 2007).
Their observations indicate that, contrary to expectations, hypoxia
occurs within allografts prior to microvascular destruction, and
it is associated with the presence of leukocyte-induced angio-
genesis. This observation is consistent with extensive studies by
Rakesh Jains group demonstrating that pathological neoangiogen-
esis and its association with abnormal blood ﬂow patterns within
a tumor is ineffective to support tissue oxygenation (Goel et al.,
2011).
Angiogenesis has been demonstrated to occur in allografts with
evidence of chronic rejection in association with allograft vas-
culopathy (Atkinson et al., 2005). Similar to our studies in the
huSCID (discussed above), as well as those reported by Babu
et al. (2007), increased capillary density within the parenchyma
of cardiac allografts has been found to be associated with T cell
and monocyte inﬁltrates (Tanaka et al., 1994). Also, neovessels
within the intima of large vessels with vasculopathy lesions have
been found to be spatially associated with inﬂammatory inﬁltrates
(Tanaka et al., 1994; Denton et al., 2004). These neovessels within
allografts are activated, in asmuch as they express cell surface adhe-
sion molecules and MHC class II. Thus, the angiogenesis reaction
itself may be pro-inﬂammatory in as much as it has potential
to mediate the recruitment and the activation of local inﬁltrates
(Atkinson et al., 2005).
Collectively, these ﬁndings illustrate that leukocyte-induced EC
proliferation/angiogenesis occurs at different sites within allo-
grafts.We propose that the abnormal angiogenicmicrovasculature
may be causative of disease, and that local tissue hypoxia is the
result, rather than the primary stimulus of the response (Jain,
2005; Figure 1). This paradigm explains in part how the intragraft
microenvironment functions to initiate and sustain the develop-
ment of chronic allograft rejection.Othermajor issues relate to the
production of cytokines and growth factors that initiate EndMT,
illustrated in Figure 2. This will be discussed in more detail below.
OVERLAPPING NATURE OF INFLAMMATION AND
ANGIOGENESIS AND THE DEVELOPMENT OF CHRONIC
REJECTION
During inﬂammation, the leukocyte-induced angiogenesis reac-
tion may be associated with local areas of tissue hypoxia and tissue
injury (illustrated in Figure 1). To this end, it is important to
note that angiogenesis factors such asVEGF have been reported to
be overexpressed in all models of chronic inﬂammation, includ-
ing models of chronic rejection, and their expression has been
found to be associated with disease progression (Leibovich et al.,
1987; Folkman and Brem, 1992; Cotran, 1994; Majno, 1998; Ezaki
et al., 2001; Ferrara, 2005). Consistent with this possibility, block-
ade of individual angiogenesis factors, including VEGF–VEGFR
interactions, in animal models has been found to attenuate the
progression of the chronic rejection disease process (Lemstrom
et al., 2002; Nykanen et al., 2003; Reinders et al., 2003a; Denton
et al., 2004; Sho et al., 2005; Malmstrom et al., 2008).
On the other hand, immune inﬂammation and the angiogene-
sis response can be antagonistic. For instance, some angiogenesis
factors such as ﬁbroblast growth factor (FGF) may inhibit adhe-
sion molecule expression and have anti-inﬂammatory effects (Jain
et al., 1996; Melder et al., 1996). Some inﬂammatory mediators
such as IFNγ or the IFNγ-inducible chemokine CXCL10/IP-10
can be anti-angiogenic (Strieter et al., 1995a; Boulday et al., 2006).
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Moreover, the competitive binding of chemokines to their recep-
tors (and vice versa) results in competition for angiogenesis and
inﬂammation (Strieter et al., 1995b). So, how is it possible that the
evolution of the leukocyte-induced angiogenesis response can be
associatedwith pro-inﬂammation?Neovessels at sites of angiogen-
esis express adhesion molecules and chemokines and can facilitate
the recruitment of leukocytes in part via enhanced leukocyte–
endothelial adhesion events (Melder et al., 1996; Detmar et al.,
1998; Kim et al., 2001; Reinders et al., 2003a). In addition, media-
tors of the leukocyte-induced angiogenesis reaction, such asVEGF,
induce the expression of EC adhesion molecules [including E-
selectin, ICAM-1, and VCAM-1 (Melder et al., 1996; Kim et al.,
2001)] andpro-inﬂammatory chemokines [such asCXCL10/IP-10
and MCP-1 (Marumo et al., 1999; Reinders et al., 2003a; Boulday
et al., 2006)]. Also, as will be discussed below, VEGF can serve
as a potent leukocyte chemoattractant via direct interactions with
its receptors expressed on subsets of monocyte/macrophages and
T cells (Barleon et al., 1996; Shin et al., 2009; Basu et al., 2010;
Suzuki et al., 2010). Therefore, once established within allografts,
the initial EC activation response that results in proliferation and
angiogenesis also facilitates inﬂammation. In contrast, inﬂamma-
tory mediators can both stimulate and inhibit angiogenesis. Thus,
the balance between the relative production of pro- versus anti-
angiogenic factors in the course of the immune response will
determine the inducible neovascular response, resulting in vas-
cular repair or injury, and this process may be a key determinant
of the outcome of rejection.
Collectively, these observations suggest that the overlapping
nature of inﬂammation and angiogenesis create an environ-
ment that is critical to shape the rejection process. They also
imply that pharmacologic manipulation of the EC response to
injury or leukocyte-induced angiogenesis will target the patho-
logical intragraft microenvironment and interrupt chronic rejec-
tion. Indeed, in animal models, several angiogenesis inhibitors
have been reported to slow the progression of chronic rejec-
tion (Lemstrom et al., 2002; Denton et al., 2004; Reinders et al.,
2006; Malmstrom et al., 2008). PTK787, a selective VEGFR pro-
tein tyrosine kinase angiogenesis inhibitor was found to attenuate
the development of interstitial ﬁbrosis and allograft vasculopathy
in well-established rat cardiac and renal transplantation models
(Lemstrom et al., 2002; Malmstrom et al., 2008). Also, TNP-470, a
synthetic fumagillin derivative and a well-established angiogenesis
inhibitor was found to interrupt the progression of inﬂamma-
tion, intragraft ﬁbrosis, and the degree of allograft vasculopathy
in the Fischer 344 into Lewis rat cardiac allograft model (Denton
et al., 2004). Furthermore, we ﬁnd that endostatin, another well-
established angiogenesis inhibitor prevents the progression of allo-
graft vasculopathy in the MHC class II mismatched B6.C-H2bm12
into C57BL/6 mouse model of chronic rejection (Contreras and
Briscoe, unpublished observations). Therefore, it appears that
transient interruption therapy with angiogenesis inhibitors has
potential to normalize the vasculature and inhibit the progression
of chronic rejection.
To this end, it is important to note that the mTOR kinase
and its associated signaling pathway has profound effects on EC
proliferation in vitro and in vivo (Dormond et al., 2007; Contr-
eras et al., 2008). We believe that mTOR inhibitors represent the
ﬁrst-in-kind angiogenesis inhibitor agents that are currently being
used therapeutically in humans following transplantation. Fur-
thermore, we suggest that this biological effect may account for
some of their ability to retard the progression of chronic rejec-
tion (Contreras et al., 2008). Several reports have indicated that a
switch from calcineurin inhibitor therapy to an mTOR inhibitor
based regimen (interruption protocol) in humans slows the pro-
gression of chronic rejection (Oberbauer et al., 2005; Schena et al.,
2009; Arora et al., 2011). These observations support the possibil-
ity that angiogenesis inhibitors have potential as therapeutics in
the future.
ENDOTHELIAL CELL TO MESENCHYMAL TRANSITION:
POSSIBLE FINAL END RESULT OF LEUKOCYTE-INDUCED OR
PATHOLOGICAL ANGIOGENESIS
The Kalluri group demonstrated that EC within cardiac allo-
grafts appear to undergo a process of mesenchymal transition to
ﬁbroblasts in association with inﬂammation and chronic rejection
(Zeisberg et al., 2007a). This process, called EndMT by several lab-
oratories results from the dedifferentiation of EC, such that they
lose their endothelial phenotype and gain the expression of mes-
enchymal markers (illustrated in Figure 2). In this manner, the
process of EndMT is characterized by the loss of well-established
EC molecules including CD31 and CD34, and the gain in expres-
sion of ﬁbroblast-speciﬁc protein 1 (FSP1), alpha-smooth muscle
actin (Zeisberg et al., 2007a,b), as well as other non-EC molecules
(Kokudo et al., 2008). In vitro, it is reported, that EndMT occurs
in response to both TGFβ1 (Arciniegas et al., 1992) and TGFβ2
(Medici et al., 2010), but the stimuli for mesenchymal transition
in vivo are poorly understood. The process of EndMT occurs in
association with pericyte loss, when EC are denuded from their
basement membrane. Denuded EC and pericytes migrate into the
surrounding tissue, where they are exposed to TGFβ that may
be produced locally by multiple cell types and/or delivered into
the graft by monocyte/macrophages (Jain et al., 2002; Booth and
Bishop, 2010), thus leading to their differentiation into ﬁbroblasts
(illustrated in Figure 2).
Endothelial-to-mesenchymal transition is well-established to
occur during embryonic development of the heart, in normal
wound healing and in several different cancers (Markwald et al.,
1975; Zeisberg et al., 2007b). It has also been implicated in chronic
ﬁbrotic disease states including atherosclerosis, pulmonary hyper-
tension, cardiac ﬁbrosis, and diabetic nephropathy (Zeisberg et al.,
2007a; Li et al., 2009; Hashimoto et al., 2010). In cancer, EndMT
has been reported to account for up to 40% of cancer-associated
ﬁbroblasts, and the process has been found to alter the microen-
vironment in several ways (Zeisberg et al., 2007b). EC that have
undergone EndMT produce collagen, deposit extracellular matrix
molecules, and secrete pro-ﬁbrotic factors including TGFβ, lead-
ing to a self-perpetuating cycle of events. In contrast, its role in
allograft rejection has not been well characterized, and it remains
controversial whether EndMT is primarily related to pericyte loss
and their migration into the local tissue, or whether it is truly
related to EC dedifferentiation (Humphreys et al., 2010). Regard-
less of whether the pericyte and/or the EC dedifferentiates into the
collagen-producing cell, the process, and long-term consequence
of microvascular destruction is ﬁbrosis.
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Since the intragraft microenvironment has similarities to
the tumor microenvironment (i.e., abnormal microvessels, local
hypoxia, TGFβ, high VEGF, mononuclear cell inﬁltrates), we have
speculated that pathological and/or leukocyte-induced angiogen-
esis will precede EndMT within allografts (illustrated in Figure 2).
Consistent with this possibility, proliferating EC have been shown
to be associated with alloimmune targeting and chronic rejec-
tion (Sis et al., 2009; Osasan et al., 2011). In addition, we have
found that proliferating EC aremost susceptible to EndMT in vitro
in the presence of inﬂammatory cytokines, TGFβ, and hypoxia.
In contrast, we ﬁnd that EC that have not undergone multiple
rounds of proliferation are not as susceptible to EndMT (Woda
and Briscoe, unpublished observations). It will be important to
understand if intragraft cytokines or growth factors that acti-
vate EC can initiate this pathological process and how VEGF
functions in the EndMT process. An alternate hypothesis is that
the intragraft cytokine milieu and/or hypoxia within allografts
at times of leukocyte-induced angiogenesis alters pericyte biol-
ogy which becomes a central determinant of both the loss of the
microvasculature and differentiation into ﬁbroblasts. Thus, there
is a need for research in this area as it is a potential target of future
therapeutics.
VASCULAR ENDOTHELIAL GROWTH FACTOR: A CENTRAL
PLAYER IN THE CHRONIC REJECTION INTRAGRAFT
MICROENVIRONMENT
By deﬁnition, the development of acute allograft rejection involves
a marked inﬂammatory reaction, characterized by the recruit-
ment of leukocytes and an intense cellular and humoral attack
on the graft (Ingulli et al., 2009). By contrast, chronic rejection is
a more insidious process involving delayed type hypersensitivity
mechanisms and is characterized by mononuclear cell inﬁltra-
tion, an obliterative vasculopathy, and progressive ﬁbrosis (Libby
and Pober, 2001; Ingulli et al., 2009). Over the past 10–15 years,
VEGF has emerged as an important player in the rejection process,
and its expression has been reported by several groups to be
associated with both acute and chronic allograft rejection (Torry
et al., 1995; Pilmore et al., 1999; Lemstrom et al., 2002; Rein-
ders et al., 2003b, 2006; Malmstrom et al., 2008). In one study
(Pilmore et al., 1999), VEGF expression was found to be most
striking in the interstitium of human renal allografts in associa-
tion with CD68+ monocyte/macrophage inﬁltrates and evidence
of chronic rejection. In another study (Torry et al., 1995), the
expression of VEGF was found to be associated with ﬁbrin depo-
sition, and was conﬁned to areas with monocyte/macrophage
inﬁltrates. In our own analyses, we observed intenseVEGF expres-
sion within human cardiac allografts localized to both inﬂam-
matory cell inﬁltrates as well as to vascular EC in association
with acute and chronic rejection (Reinders et al., 2003b). More-
over, we found that persistent intragraft VEGF overexpression
identiﬁed patients at high risk for the development of chronic
allograft vasculopathy/chronic rejection (Reinders et al., 2003b).
Furthermore, human transplant recipients with genotypes encod-
ing high VEGF production are at increased risk for the devel-
opment of rejection (Shahbazi et al., 2002; Girnita et al., 2008).
Levels of VEGF increase signiﬁcantly in the serum and urine of
patients in association with cardiac and renal allograft rejection
respectively, and in most cases return to baseline after effective
treatment of the rejection episode (Abramson et al., 2002; Peng
et al., 2008). It is thus possible that serum levels of VEGF may
serve as a reliable biomarker of the development of allograft vas-
culopathy following human cardiac transplantation (Daly et al.,
2011).
VEGF may be delivered into allografts in the course of rejection
by inﬁltrating monocytes and by activated T cells (Leibovich et al.,
1987; Leibovich and Wiseman, 1988; Freeman et al., 1995; Melter
et al., 2000). Alternatively, VEGF may be induced locally within
the allograft as a result of cellular interactions among activated
platelets and EC (Chiodoni et al., 2006; Dormond et al., 2008).
Nevertheless, the local overexpression of VEGF within allografts
results in the development of chronic rejection and allograft vascu-
lopathy (Lemstrom et al., 2002). Taken together, there is extensive
data to support the hypothesis that VEGF is mechanistic in the
process of chronic allograft rejection.
The major stimulus for VEGF expression is hypoxia (Shweiki
et al., 1992; Mukhopadhyay et al., 1995; Goel et al., 2011), but
other factors that can upregulate local tissue VEGF production
include paracrine effects of hormones, glucose andprostaglandins,
as well as cytokine/growth factor modulators of protein kinase
C, nitric oxide, and stimulators of adenylate cyclase (Brown
et al., 1997). Several cytokines, including IL-1, TNF, and IL-
6, have been found to induce the expression of VEGF and/or
VEGF receptors (Leibovich et al., 1987; Giraudo et al., 1998;
Amano et al., 2004; Huang et al., 2004). In addition, we have
demonstrated that the ligation of CD40 by CD154 (CD40 lig-
and, expressed by activated platelets and T cells) is potent for
local tissue induction of VEGF expression (Melter et al., 2000;
Dormond et al., 2008). In this manner, it is not surprising that
cell-mediated immune inﬂammation is associated with VEGF–
VEGFR biological responses. Furthermore, since multiple VEGF-
inducing factors are present within allografts at different times
post transplantation, one might conclude that VEGF expression,
and VEGF-dependent biological responses should be characteris-
tic features of both the initiation and the maintenance of chronic
rejection.
BIOLOGY OF VEGF–VEGFR INTERACTIONS
As its name suggests,VEGF classically functions as a potent angio-
genesis factor, and as such it was originally proposed to facili-
tate microvascular repair following ischemic injury (Kang et al.,
2001a,b; Mayer, 2011) as well as injury following inﬂammatory
insults (Choi et al., 2000; Reinders et al., 2006). VEGF is a 45-
kDa protein produced by most cell types including cells of the
immune system such as monocyte/macrophages and activated T
cell subsets (Freeman et al., 1995; Brown et al., 1997; Polverini,
1997; Melter et al., 2000; Basu et al., 2010). It is a heparin-binding
homodimeric glycoprotein with several protein variants of 206,
189, 164, 145, and 121 amino acids that arise from the alternative
splicing of a single gene (Leung et al., 1989; Tischer et al., 1991).
Intense research beyond the scope of this review, has clariﬁed the
function of VEGF in EC, where it mediates migration, growth,
survival as well as activation responses including the expression of
adhesion molecules and chemokines (Alon et al., 1995; Klagsbrun
and D’Amore, 1996; Melder et al., 1996; Brown et al., 1997; Gerber
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et al., 1999; Kim et al., 2001; Ferrara, 2005; Boulday et al., 2006;
Lee et al., 2007).
The biological activities of VEGF are mediated via interactions
with its receptors, Flt-1 (VEGF receptor 1), KDR (VEGF receptor
2), andneuropilin-1 (Shalaby et al., 1995;Klagsbrun andD’Amore,
1996; Brown et al., 1997; Miao and Klagsbrun, 2000; Ferrara, 2005;
Takahashi and Shibuya, 2005; Matsumoto and Mugishima, 2006).
Several studies have shown that signaling mediated via KDR is
critical for the VEGF-induced response (Zeng et al., 2001). For
instance, many of the biological properties of VEGF can be inhib-
ited by neutralization of KDR; and inhibition of KDR has similar
effects as neutralization of VEGF in vivo in inﬂammatory diseases
(Brown et al., 1997; Watanabe et al., 2004, 2005; Ferrara, 2005),
including allograft rejection (Reinders et al., 2003a; Sho et al.,
2005).Also, knockout of eitherVEGForKDR results in embryonic
lethality due to inhibition of angioblast differentiation and vascu-
logenesis (Shalaby et al., 1995; Ferrara et al., 1996). Classically, it
is thought that neuropilin-1 serves as an accessory co-receptor for
KDR to bind VEGF and mediate crosslinking to KDR (Klagsbrun
and D’Amore, 1996; Matsumoto and Mugishima, 2006). However,
some studies have suggested that neuropilin-1 might also mediate
signaling directly in response to the semaphorin 3 family of pro-
teins (Wang et al., 2003; Catalano et al., 2006; Mizui et al., 2009;
Suzuki et al., 2008). VEGF also signals through Flt-1 to initiate a
direct signaling response, but its interaction with Flt-1 may inhibit
KDR-induced responses in EC (Zeng et al., 2002). Thus, VEGF
inducible responses in different cells can be determined according
to the proﬁle of expression of its receptors and thus, the select
VEGFR-dependent signal.
All VEGF receptors are expressed by EC, but individual recep-
tors are also expressed by different leukocyte subsets indicating
that VEGF may have direct effects on the immune response (Bar-
leon et al., 1996; Bruder et al., 2004; Sarris et al., 2008; Shin et al.,
2009; Basu et al., 2010; Suzuki et al., 2010). Flt-1 and neuropilin-
1 are expressed by human monocytes and APCs (Barleon et al.,
1996; Romeo et al., 2002; Bourbie-Vaudaine et al., 2006; Chapoval
et al., 2009), and VEGF is known to induce activation responses
and chemotactic activity inmonocytes in part via interactionswith
Flt-1 (Barleon et al., 1996;Clauss et al., 1996; Laxmanan et al., 2005;
Chapoval et al., 2009). VEGF–VEGFR interactions also promote
the differentiation of monocytes into pro-inﬂammatory (Chapo-
val et al., 2009) or immunoregulatory (Gabrilovich et al., 1998;
Laxmanan et al., 2005) APCs, but its effect is likely dependent
on individual VEGFR(s) expressed by the APC (Laxmanan et al.,
2005; Chapoval et al., 2009).
Moreover, several recent studies have indicated that T cell sub-
sets can express VEGFRs, including Flt-1, KDR, and neuropilin-1
(Dias et al., 2000; Tordjman et al., 2002; Mor et al., 2004; Sar-
ris et al., 2008; Basu et al., 2010; Edelbauer et al., 2010; Ziogas
et al., 2011). In our studies (Basu et al., 2010; Edelbauer et al.,
2010), we ﬁnd low negligible levels of expression of all VEGFRs
on freshly isolated populations of unactivated CD4+ and CD8+ T
cells. However, we have observed that the expression of Flt-1 and
KDR increase following mitogen-dependent activation. In addi-
tion, we have found high levels of KDR on memory CD45RO+
populations of CD4+ T cells (Basu et al., 2010). In general, KDR
and Flt-1 are reported to be the dominant VEGFRs expressed on
T effector cells (Basu et al., 2010; Edelbauer et al., 2010; Zhang
et al., 2010; Ziogas et al., 2011). In contrast, it is reported that
neuropilin-1 is selectively expressed at high levels on populations
of CD4+CD25+FoxP3+ T regulatory cells (Bruder et al., 2004;
Sarris et al., 2008). One study indicated that T regulatory cells may
also express KDR (Suzuki et al., 2010). Neuropilin-1 has also been
reported to be expressed on populations of human naïve T cells,
where it functions to support the initiation of T cell activation in
primary immune responses (Tordjman et al., 2002).
Collectively, these ﬁndings support the possibility that intra-
graft VEGF may interact with different T cell subsets in the course
of the rejection process. VEGF may function as a potent chemoat-
tractant for effector and memory CD4+ and CD8+ T cells, and
may thus promote inﬂammation in association with acute and
chronic allograft rejection. Consistent with this possibility, the
blockade of VEGF or VEGFR interactions with T cells inhibits
intragraft lymphocyte trafﬁcking (Reinders et al., 2003a; Sho et al.,
2005; Edelbauer et al., 2010; Zhang et al., 2010) as well as reacti-
vation responses (Basu et al., 2010) in human model systems. In
experimental animal models, the local overexpression of VEGF,
and VEGF–VEGFR interactions also facilitate lymphocyte traf-
ﬁcking (Reinders et al., 2003a; Lee et al., 2004; Kim et al., 2009;
Edelbauer et al., 2010; Zhang et al., 2010) and activation including
the augmentation of Th1 (Chapoval et al., 2009), Th2 (Lee et al.,
2004), and Th17 (Kim et al., 2009) effector responses. The mech-
anism(s) by which local tissue VEGF elicits signals for migration
and activation/reactivation responses is the subject of ongoing
investigations.
PRO-INFLAMMATORY EFFECTS OF VEGF–VEGF RECEPTOR
INTERACTIONS
As discussed above,VEGF may act as a pro-inﬂammatory cytokine
in vivo in several chronic diseases (Fava et al., 1994; Koch et al.,
1994; Duh and Aiello, 1999; Ferrara and Alitalo, 1999; Griga et al.,
1999;Hoshino et al., 2001; Kanazawa et al., 2001;McDonald, 2001;
Walsh and Pearson, 2001; Kim et al., 2009; Detoraki et al., 2010),
and its ability to function as a pro-inﬂammatory cytokine in part
relates to its interactions with its receptors expressed on leuko-
cytes (Barleon et al., 1996; Shin et al., 2009; Basu et al., 2010;
Edelbauer et al., 2010; Suzuki et al., 2010; Zhang et al., 2010). Its
ability to interact directly with monocytes (via Flt-1), NK T cells,
and CD3+ T cells (via Flt-1 and KDR) to facilitate chemotactic
activity is likely of great pathophysiological importance in rejec-
tion (Edelbauer et al., 2010; Zhang et al., 2010). In addition,VEGF
induces the expression of adhesion molecules and chemokines in
EC (Melder et al., 1996;Marumo et al., 1999;Kim et al., 2001; Rein-
ders et al., 2003a; Boulday et al., 2006), and classically enhances
vascular permeability (Brown et al., 1997; Basu et al., 2001). All of
these events are characteristic of acute and chronic inﬂammation
(Cotran, 1994).
In models of chronic rejection, it was demonstrated that
overexpression of VEGF mobilizes bone marrow derived mono-
cyte/macrophages and accelerates the development of allograft
vasculopathy (Lemstrom et al., 2002; Zhao et al., 2002). Further,
it was found that blockade of VEGF receptor 2 (KDR) signaling
decreases monocyte recruitment into vascular lesions and atten-
uates the development of graft arteriosclerosis (Lemstrom et al.,
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2002; Zhao et al., 2002).We found that KDR is expressed on CD3+
inﬁltrates within rejecting human allografts in vivo, and that both
anti-VEGF and anti-KDR antibodies inhibit the transmigration
of CD4+ and CD8+ T cells across activated EC using an in vitro
live-time transmigration model (Edelbauer et al., 2010). Using a
huSCID mouse model of lymphocyte trafﬁcking, we also demon-
strated that KDR-expressing lymphocytes migrate into human
skin in vivo, and that migration is reduced in mice treated with
a blocking anti-VEGF antibody (Edelbauer et al., 2010). Collec-
tively, these observations demonstrate that induced expression of
KDR on subsets of T cells, and locally expressed VEGF facilitate
lymphocyte chemotaxis. They support a model whereby intra-
graft VEGF mediates the localization of T cells in association with
chronic rejection.
In another recent report, Zhang et al. (2010) used an anti-
human VEGF antibody to study the effect of VEGF blockade on
the development of allograft vasculopathy in a humanized model
in SCID mice. They found that anti-VEGF inhibited intragraft
accumulation of T cells without affecting T cell activation. In addi-
tion, theyobserved that anti-VEGF treatment inhibitedneointimal
formation within human coronary artery grafts in the humanized
mouse. The authors suggested that theT cell chemoattractive effect
of VEGF was mediated in part via interactions with a subpopula-
tion of Flt-1-expressing CD3+ T cells. Thus, intragraft VEGF may
also contribute to vascular remodeling and allograft vasculopathy
by enhancing T cell recruitment into the intima of large vessels.
Collectively, these observations indicate that VEGF has potent
pro-inﬂammatory properties under pathological conditions in
association with the development of chronic rejection and allo-
graft vasculopathy.
OVERALL SUMMARY AND PERSPECTIVE
In this review, we have discussed a paradigm where leukocyte-
induced angiogenesis, local tissue hypoxia, and the overexpression
of VEGF sustain an intragraft microenvironment that fosters the
development of chronic allograft rejection. We have also deﬁned
EC-based events within the allograft microenvironment that are
associated with chronic rejection. The ﬁrst are changes in the
microcirculation resulting from destruction of the microvascu-
lature. The second are changes in the microcirculation resulting
from EC proliferation and leukocyte-induced angiogenesis. Both
events are likely to disrupt normal blood ﬂow patterns within
the graft and result in local areas of tissue hypoxia. In addition,
EC undergoing proliferation express adhesion molecules and
chemokines that support pro-inﬂammation, providing another
mechanism whereby the angiogenesis reaction may sustain ongo-
ing tissue injury. A third intragraft determinant of chronic disease
is the development of EndMT. While the mechanism underly-
ing EndMT is controversial, there is sufﬁcient evidence to suggest
that inﬂammation and EC proliferation is associated with peri-
cyte loss, which likely precedes microvascular capillary loss and
the development of ﬁbrosis. Whether the pericyte or the EC, or
both, ultimately dedifferentiate into collagen-producing cells is
being debated. Nevertheless, it has been reported that cytokines
and growth factors, including TGFβ (Booth and Bishop, 2010),
can accelerate this ﬁbrotic reaction. Although beyond the scope of
this review, TGFβmay also be a key aspect of the chronic rejection
intragraftmicroenvironment (Jain et al., 2000). Finally,wepropose
that a fourth and key determinant of chronic rejection is intragraft
overexpression of VEGF,which functions to facilitate both inﬂam-
mation and pathological EC proliferation/angiogenesis. While
VEGF may be delivered into allografts by inﬂammatory inﬁltrates,
such as monocytes and activated T cells, the immune response
can also elicit the local overproduction of VEGF within the graft.
Overall, in this review we provide insight into novel aspects of
the intragraft microenvironment that contribute to the develop-
ment of chronic rejection and long-term attrition of allografts
following transplantation. The importance of this paradigm is
that it identiﬁes key areas for future therapeutic targeting to pre-
vent the progression of chronic rejection following solid organ
transplantation.
ACKNOWLEDGMENTS
The work cited in this review was supported by NIH Grants
R01AI046756, RO1HL074436, R01AI092305-01, R21HL104602-
01, T32DK007726-28, T32HL07572, and UL1RR025758 (Harvard
Catalyst). Sarah Bruneau was supported by a Fellowship grant
from the American Society of Transplantation. Alan Contreras
was supported by a Fellowship grant from theAmerican Society of
Transplant Surgeons. The authors wish to acknowledge past mem-
bers of the laboratory who worked on these projects, and we are
grateful for the support of technicians for their ongoing efforts.
We are also indebted to the support of our collaborators, most
especially Dr. Rakesh Jain for stimulating our interest in this area
of research, and to Drs. Debabrata Mukhopadhyay and Michael
Klagsbrun for ongoing scientiﬁc interactions.
REFERENCES
Abramson, L. P., Pahl, E., Huang,
L., Stellmach, V., Rodgers, S.,
Mavroudis, C., Backer, C. L.,
Arensman, R. M., and Craw-
ford, S. E. (2002). Serum vascu-
lar endothelial growth factor as
a surveillance marker for cellu-
lar rejection in pediatric cardiac
transplantation. Transplantation 73,
153–156.
Alon, T., Hemo, I., Itin, A., Pe’Er, J.,
Stone, J., and Keshet, E. (1995). Vas-
cular endothelial growth factor acts
as a survival factor for newly formed
retinal vessels and has implications
for retinopathy of prematurity. Nat.
Med. 1, 1024–1028.
Amano, K., Okigaki, M., Adachi, Y.,
Fujiyama, S., Mori, Y., Kosaki,
A., Iwasaka, T., and Matsubara,
H. (2004). Mechanism for IL-
1 beta-mediated neovascularization
unmasked by IL-1 beta knock-out
mice. J. Mol. Cell. Cardiol. 36,
469–480.
Arciniegas, E., Sutton, A. B., Allen,
T. D., and Schor, A. M. (1992).
Transforming growth factor beta
1 promotes the differentiation
of endothelial cells into smooth
muscle-like cells in vitro. J. Cell. Sci.
103(Pt 2), 521–529.
Arora, S., Ueland, T., Wennerblom, B.,
Sigurdadottir,V.,Eiskjaer,H.,Botker,
H. E., Ekmehag, B., Jansson, K.,
Mortensen, S. A., Saunamaki, K.,
Simonsen, S., Gude, E., Bendz, B.,
Solbu, D., Aukrust, P., and Gullestad,
L. (2011). Effect of everolimus intro-
duction on cardiac allograft vascu-
lopathy – results of a randomized,
multicenter trial.Transplantation 92,
235–243.
Atkinson, C., Southwood, M., Pitman,
R., Phillpotts, C., Wallwork, J., and
Goddard, M. (2005). Angiogene-
sis occurs within the intimal pro-
liferation that characterizes trans-
plant coronary artery vasculopa-
thy. J. Heart Lung Transplant. 24,
551–558.
Auerbach, R., and Sidky, Y. A. (1979).
Nature of the stimulus leading to
lymphocyte-induced angiogenesis.
J. Immunol. 123, 751–754.
Frontiers in Immunology | Immunological Tolerance April 2012 | Volume 3 | Article 54 | 8
Bruneau et al. The intragraft microenvironment
Aydin, Z., van Zonneveld, A. J., de
Fijter, J. W., and Rabelink, T. J.
(2007). New horizons in prevention
and treatment of ischaemic injury
to kidney transplants. Nephrol. Dial.
Transplant. 22, 342–346.
Babu, A. N., Murakawa, T., Thurman,
J. M., Miller, E. J., Henson, P. M.,
Zamora, M. R., Voelkel, N. F., and
Nicolls, M. R. (2007). Microvascular
destruction identiﬁes murine allo-
grafts that cannot be rescued from
airway ﬁbrosis. J. Clin. Invest. 117,
3774–3785.
Barleon, B., Sozzani, S., Zhou, D.,
Weich, H. A., Mantovani, A., and
Marme, D. (1996). Migration of
human monocytes in response to
vascular endothelial growth fac-
tor (VEGF) is mediated via the
VEGF receptor ﬂt-1. Blood 87,
3336–3343.
Basu, A., Hoerning, A., Datta, D., Edel-
bauer,M., Stack,M. P.,Calzadilla,K.,
Pal, S., and Briscoe, D. M. (2010).
Cutting edge: vascular endothe-
lial growth factor-mediated signal-
ing in human CD45RO+ CD4+
T cells promotes Akt and ERK
activation and costimulates IFN-
gammaproduction. J. Immunol. 184,
545–549.
Basu, S., Nagy, J. A., Pal, S., Vasile,
E., Eckelhoefer, I. A., Bliss, V. S.,
Manseau, E. J., Dasgupta, P. S.,
Dvorak, H. F., and Mukhopad-
hyay, D. (2001). The neurotrans-
mitter dopamine inhibits angio-
genesis induced by vascular per-
meability factor/vascular endothe-
lial growth factor. Nat. Med. 7,
569–574.
Bishop, G. A., Waugh, J. A., Lan-
ders, D. V., Krensky, A. M., and
Hall, B. M. (1989). Microvascu-
lar destruction in renal trans-
plant rejection. Transplantation 48,
408–414.
Booth, A. J., and Bishop, D. K.
(2010). TGF-beta, IL-6, IL-17 and
CTGF direct multiple pathologies of
chronic cardiac allograft rejection.
Immunotherapy 2, 511–520.
Boulday, G., Haskova, Z., Reinders,
M. E., Pal, S., and Briscoe, D. M.
(2006). Vascular endothelial growth
factor-induced signaling pathways
in endothelial cells that mediate
overexpression of the chemokine
IFN-gamma-inducible protein of 10
kDa in vitro and in vivo. J. Immunol.
176, 3098–3107.
Bourbie-Vaudaine, S., Blanchard, N.,
Hivroz, C., and Romeo, P. H. (2006).
Dendritic cells can turn CD4+ T
lymphocytes into vascular endothe-
lial growth factor-carrying cells
by intercellular neuropilin-1
transfer. J. Immunol. 177,
1460–1469.
Briscoe, D. M., Alexander, S. I., and
Lichtman, A. H. (1998). Interac-
tions between T lymphocytes and
endothelial cells in allograft rejec-
tion. Curr. Opin. Immunol. 10,
525–531.
Briscoe, D. M., Dharnidharka, V. R.,
Isaacs, C., Downing, G., Prosky,
S., Shaw, P., Parenteau, N. L., and
Hardin-Young, J. (1999). The allo-
geneic response to cultured human
skin equivalent in the hu-PBL-SCID
mouse model of skin rejection.
Transplantation 67, 1590–1599.
Briscoe, D. M., and Pal, S. (2008).
Assessing the vascular effects of
early erythropoietin use in pedi-
atric renal transplant recipients.Nat.
Clin. Pract. Nephrol. 4, 136–137.
Briscoe, D. M., and Sayegh, M.
H. (2002). A rendezvous before
rejection: where do T cells meet
transplant antigens? Nat. Med. 8,
220–222.
Brown, L. F., Detmar, M., Claffey, K.,
Nagy, J. A., Feng, D., Dvorak, A.
M., and Dvorak, H. F. (1997). Vas-
cular permeability factor/vascular
endothelial growth factor: a multi-
functional angiogenic cytokine. EXS
79, 233–269.
Brown, L. F., Olbricht, S. M., Berse,
B., Jackman, R. W., Matsueda,
G., Tognazzi, K. A., Manseau,
E. J., Dvorak, H. F., and Van
de Water, L. (1995). Overexpres-
sion of vascular permeability factor
(VPF/VEGF) and its endothelial cell
receptors in delayed hypersensitiv-
ity skin reactions. J. Immunol. 154,
2801–2807.
Bruder, D., Probst-Kepper, M., Westen-
dorf, A. M., Geffers, R., Beissert, S.,
Loser, K., von Boehmer, H., Buer, J.,
and Hansen, W. (2004). Neuropilin-
1: a surface marker of regula-
tory T cells. Eur. J. Immunol. 34,
623–630.
Carmeliet, P., and Jain, R. K. (2000).
Angiogenesis in cancer and other
diseases. Nature 407, 249–257.
Catalano, A., Caprari, P., Moretti, S.,
Faronato, M., Tamagnone, L., and
Procopio, A. (2006). Semaphorin-
3A is expressed by tumor cells and
alters T-cell signal transduction and
function. Blood 107, 3321–3329.
Chapoval, S. P., Lee,C. G., Tang,C., Kee-
gan, A. D., Cohn, L., Bottomly, K.,
and Elias, J. A. (2009). Lung vascu-
lar endothelial growth factor expres-
sion induces local myeloid dendritic
cell activation. Clin. Immunol. 132,
371–384.
Chiodoni, C., Iezzi, M., Guiducci, C.,
Sangaletti, S., Alessandrini, I., Ratti,
C., Tiboni, F., Musiani, P., Granger,
D. N., and Colombo, M. P. (2006).
Triggering CD40 on endothelial cells
contributes to tumor growth. J. Exp.
Med. 203, 2441–2450.
Choi, Y. J., Chakraborty, S., Nguyen,
V., Nguyen, C., Kim, B. K., Shim,
S. I., Suki, W. N., and Truong, L.
D. (2000). Peritubular capillary loss
is associated with chronic tubu-
lointerstitial injury in human kid-
ney: altered expression of vascu-
lar endothelial growth factor. Hum.
Pathol. 31, 1491–1497.
Clauss, M., Weich, H., Breier, G., Knies,
U., Rockl, W., Waltenberger, J., and
Risau, W. (1996). The vascular
endothelial growth factor receptor
Flt-1 mediates biological activities.
Implications for a functional role of
placenta growth factor in monocyte
activation and chemotaxis. J. Biol.
Chem. 271, 17629–17634.
Contreras, A. G., and Briscoe, D. M.
(2007). Every allograft needs a sil-
ver lining. J. Clin. Invest. 117,
3645–3648.
Contreras, A. G., Dormond, O., Edel-
bauer, M., Calzadilla, K., Hoern-
ing, A., Pal, S., and Briscoe, D. M.
(2008). mTOR-understanding the
clinical effects. Transplant. Proc. 40,
S9–S12.
Cotran,R. S. (1994).“Inﬂammation and
repair,” in Pathologic Basis of Dis-
ease, eds R. S. Cotran,V. Kumar, and
S. L. Robbins (Philadelphia: W. B.
Saunders), 51–92.
Daly, K., Seifert, M., Stack, M., Chan-
draker, A., Zurakowski, D., Nohria,
A., Givertz, M., Karumanchi, A., and
Briscoe, D. M. (2011). Identiﬁca-
tion of highly sensitive and speciﬁc
biomarker panel for the diagnosis
of chronic rejection/allograft vas-
culopathy following human cardiac
transplantation. Am. J. Transplant.
11, 68–69.
Denton, M. D., Davis, S. F., Baum,
M. A., Melter, M., Reinders, M.
E., Exeni, A., Samsonov, D. V.,
Fang, J., Ganz, P., and Briscoe, D.
M. (2000). The role of the graft
endothelium in transplant rejec-
tion: evidence that endothelial acti-
vation may serve as a clinical marker
for the development of chronic
rejection. Pediatr. Transplant. 4,
252–260.
Denton, M. D., Magee, C., Melter,
M., Dharnidharka, V. R., Sayegh,
M. H., and Briscoe, D. M. (2004).
TNP-470, an angiogenesis inhibitor,
attenuates the development of allo-
graft vasculopathy. Transplantation
78, 1218–1221.
Detmar, M., Brown, L. F., Schon,
M. P., Elicker, B. M., Velasco, P.,
Richard, L., Fukumura, D., Mon-
sky, W., Claffey, K. P., and Jain,
R. K. (1998). Increased microvas-
cular density and enhanced leuko-
cyte rolling and adhesion in the skin
of VEGF transgenic mice. J. Invest.
Dermatol. 111, 1–6.
Detoraki, A., Granata, F., Staibano,
S., Rossi, F. W., Marone, G., and
Genovese, A. (2010). Angiogen-
esis and lymphangiogenesis in
bronchial asthma. Allergy 65,
946–958.
Dias, S., Hattori, K., Zhu, Z., Heis-
sig, B., Choy, M., Lane, W., Wu, Y.,
Chadburn, A., Hyjek, E., Gill, M.,
Hicklin, D. J., Witte, L., Moore, M.
A., and Raﬁi, S. (2000). Autocrine
stimulation of VEGFR-2 activates
human leukemic cell growth and
migration. J. Clin. Invest. 106,
511–521.
Dormond, O., Contreras, A. G., Mei-
jer, E., Datta, D., Flynn, E., Pal,
S., and Briscoe, D. M. (2008).
CD40-induced signaling in human
endothelial cells results inmTORC2-
and Akt-dependent expression of
vascular endothelial growth factor
in vitro and in vivo. J. Immunol. 181,
8088–8095.
Dormond, O., Madsen, J. C., and
Briscoe, D. M. (2007). The effects
of mTOR-Akt interactions on anti-
apoptotic signaling in vascular
endothelial cells. J. Biol. Chem. 282,
23679–23686.
Duh,E., andAiello,L. P. (1999).Vascular
endothelial growth factor and dia-
betes: the agonist versus antagonist
paradox. Diabetes 48, 1899–1906.
Edelbauer, M., Datta, D., Vos, I. H.,
Basu, A., Stack, M. P., Reinders, M.
E., Sho, M., Calzadilla, K., Ganz,
P., and Briscoe, D. M. (2010).
Effect of vascular endothelial growth
factor and its receptor KDR on
the transendothelial migration and
local trafﬁcking of human T cells
in vitro and in vivo. Blood 116,
1980–1989.
Ezaki, T., Baluk, P., Thurston, G., La
Barbara, A., Woo, C., and McDon-
ald, D. M. (2001). Time course
of endothelial cell proliferation
and microvascular remodeling in
chronic inﬂammation.Am. J. Pathol.
158, 2043–2055.
Fava, R. A., Olsen, N. J., Spencer-
Green, G., Yeo, K. T., Yeo, T. K.,
Berse, B., Jackman, R. W., Senger,
D. R., Dvorak, H. F., and Brown,
L. F. (1994). Vascular permeabil-
ity factor/endothelial growth fac-
tor (VPF/VEGF): accumulation and
expression in human synovial ﬂu-
ids and rheumatoid synovial tissue.
J. Exp. Med. 180, 341–346.
www.frontiersin.org April 2012 | Volume 3 | Article 54 | 9
Bruneau et al. The intragraft microenvironment
Ferrara, N. (2005). The role of VEGF
in the regulation of physiological
and pathological angiogenesis. EXS
209–231.
Ferrara, N., and Alitalo, K. (1999).
Clinical applications of angiogenic
growth factors and their inhibitors.
Nat. Med. 5, 1359–1364.
Ferrara, N., Carver-Moore, K., Chen,
H., Dowd, M., Lu, L., O’Shea, K.
S., Powell-Braxton, L., Hillan, K. J.,
and Moore,M.W. (1996). Heterozy-
gous embryonic lethality induced by
targeted inactivation of the VEGF
gene. Nature 380, 439–442.
Ferrara, N., and Kerbel, R. S. (2005).
Angiogenesis as a therapeutic target.
Nature 438, 967–974.
Fine, L. G., and Norman, J. T. (2008).
Chronic hypoxia as a mechanism
of progression of chronic kid-
ney diseases: from hypothesis to
novel therapeutics. Kidney Int. 74,
867–872.
Folkman, J. (1995a). Angiogenesis in
cancer, vascular, rheumatoid and
other disease. Nat. Med. 1, 27–31.
Folkman, J. (1995b). Seminars in Med-
icine of the Beth Israel Hospi-
tal, Boston. Clinical applications of
research on angiogenesis. N. Engl. J.
Med. 333, 1757–1763.
Folkman, J., and Brem, H. (1992).
“Angiogenesis and inﬂammation,” in
Inﬂammation: Basic Principles and
Clinical Correlates, eds J. I. Gallin,
I. M. Goldstein, and R. Synderman
(New York: Raven Press), 821–839.
Freeman,M. R., Schneck, F. X., Gagnon,
M. L., Corless, C., Soker, S., Nikne-
jad, K., Peoples, G. E., and Klags-
brun, M. (1995). Peripheral blood T
lymphocytes and lymphocytes inﬁl-
trating human cancers express vas-
cular endothelial growth factor: a
potential role for T cells in angio-
genesis. Cancer Res. 55, 4140–4145.
Fukumura, D., and Jain, R. K. (2007).
Tumor microvasculature and
microenvironment: targets for anti-
angiogenesis and normalization.
Microvasc. Res. 74, 72–84.
Gabrilovich, D., Ishida, T., Oyama, T.,
Ran, S., Kravtsov, V., Nadaf, S.,
and Carbone, D. P. (1998). Vascu-
lar endothelial growth factor inhibits
the development of dendritic cells
and dramatically affects the differ-
entiation of multiple hematopoi-
etic lineages in vivo. Blood 92,
4150–4166.
Gerber, H. P., Hillan, K. J., Ryan, A. M.,
Kowalski, J., Keller, G. A., Rangell,
L., Wright, B. D., Radtke, F., Aguet,
M., and Ferrara, N. (1999). VEGF
is required for growth and survival
in neonatal mice. Development 126,
1149–1159.
Giraudo, E., Primo, L., Audero, E.,
Gerber, H. P., Koolwijk, P., Soker,
S., Klagsbrun, M., Ferrara, N., and
Bussolino, F. (1998). Tumor necro-
sis factor-alpha regulates expres-
sion of vascular endothelial growth
factor receptor-2 and of its co-
receptor neuropilin-1 in human vas-
cular endothelial cells. J. Biol. Chem.
273, 22128–22135.
Girnita, D. M., Brooks, M. M., Web-
ber, S. A., Burckart, G. J., Fer-
rell, R., Zdanowicz, G., DeCroo, S.,
Smith, L., Chinnock, R., Canter, C.,
Addonizio, L., Bernstein, D., Kirklin,
J. K., Ranganathan, S., Naftel, D.,
Girnita, A. L., and Zeevi, A. (2008).
Genetic polymorphisms impact the
risk of acute rejection in pedi-
atric heart transplantation: a multi-
institutional study. Transplantation
85, 1632–1639.
Goel, S.,Duda,D.G.,Xu,L.,Munn,L. L.,
Boucher, Y., Fukumura, D., and Jain,
R. K. (2011). Normalization of the
vasculature for treatment of cancer
and other diseases. Physiol. Rev. 91,
1071–1121.
Griga, T., Voigt, E., Gretzer, B., Brasch,
F., and May, B. (1999). Increased
production of vascular endothelial
growth factor by intestinal mucosa
of patients with inﬂammatory bowel
disease. Hepatogastroenterology 46,
920–923.
Halloran, P. F., de Freitas,D. G., Einecke,
G., Famulski, K. S., Hidalgo, L. G.,
Mengel,M., Reeve, J., Sellares, J., and
Sis, B. (2010). The molecular phe-
notype of kidney transplants. Am. J.
Transplant. 10, 2215–2222.
Hanto, D. W., Maki, T., Yoon, M. H.,
Csizmadia, E., Chin, B. Y., Gallo, D.,
Konduru, B., Kuramitsu, K., Smith,
N. R., Berssenbrugge, A., Attana-
sio, C., Thomas, M., Wegiel, B.,
and Otterbein, L. E. (2010). Intra-
operative administration of inhaled
carbon monoxide reduces delayed
graft function in kidney allografts
in Swine. Am. J. Transplant. 10,
2421–2430.
Hashimoto, N., Phan, S. H., Imaizumi,
K., Matsuo, M., Nakashima, H.,
Kawabe, T., Shimokata, K., and
Hasegawa, Y. (2010). Endothelial-
mesenchymal transition in
bleomycin-induced pulmonary
ﬁbrosis. Am. J. Respir. Cell Mol. Biol.
43, 161–172.
Hoshino, M., Takahashi, M., and Aoike,
N. (2001). Expression of vascu-
lar endothelial growth factor, basic
ﬁbroblast growth factor, and angio-
genin immunoreactivity in asth-
matic airways and its relationship
to angiogenesis. J. Allergy Clin.
Immunol. 107, 295–301.
Huang, S. P., Wu, M. S., Shun, C. T.,
Wang, H. P., Lin, M. T., Kuo, M. L.,
and Lin, J. T. (2004). Interleukin-
6 increases vascular endothelial
growth factor and angiogenesis in
gastric carcinoma. J. Biomed. Sci. 11,
517–527.
Humphreys, B. D., Lin, S. L., Kobayashi,
A., Hudson, T. E., Nowlin, B. T.,
Bonventre, J. V., Valerius, M. T.,
McMahon, A. P., and Dufﬁeld, J.
S. (2010). Fate tracing reveals the
pericyte and not epithelial origin
of myoﬁbroblasts in kidney ﬁbrosis.
Am. J. Pathol. 176, 85–97.
Ingulli, E., Alexander, S. I., and Briscoe,
D. M. (2009). “Transplantation
immunology,” in Pediatric Nephrol-
ogy, eds E.D.Avner,W.E.Harmon,P.
Niaudet, and N. Yoshikawa (Berlin:
Springer-Verlag), 1835–1866.
Inoue, M., Itoh, H., Ueda, M., Naruko,
T., Kojima, A., Komatsu, R., Doi, K.,
Ogawa, Y., Tamura, N., Takaya, K.,
Igaki, T., Yamashita, J., Chun, T. H.,
Masatsugu, K., Becker, A. E., and
Nakao, K. (1998). Vascular endothe-
lial growth factor (VEGF) expression
in human coronary atherosclerotic
lesions: possible pathophysiological
signiﬁcance of VEGF in progres-
sion of atherosclerosis. Circulation
98, 2108–2116.
Jain, R. K. (2005). Normalization of
tumor vasculature: an emerging
concept in antiangiogenic therapy.
Science 307, 58–62.
Jain,R.K. (2008). Taming vessels to treat
cancer. Sci. Am. 298, 56–63.
Jain, R. K., Koenig, G. C., Dellian,
M., Fukumura, D., Munn, L. L.,
and Melder, R. J. (1996). Leuko-
cyte endothelial adhesion and angio-
genesis in tumors. Cancer Metastasis
Rev. 15, 195–204.
Jain, S., Furness, P. N., and Nicholson,
M. L. (2000). The role of transform-
ing growth factor beta in chronic
renal allograft nephropathy. Trans-
plantation 69, 1759–1766.
Jain, S., Mohamed, M. A., Sandford,
R., Furness, P. N., Nicholson, M. L.,
and Talbot, D. (2002). Sequential
protocol biopsies from renal trans-
plant recipients show an increas-
ing expression of active TGF beta.
Transpl. Int. 15, 630–634.
Johnson, D. W., Forman, C., and Vesey,
D. A. (2006). Novel renoprotective
actions of erythropoietin: new uses
for an old hormone. Nephrology
(Carlton) 11, 306–312.
Kaminski, M., and Auerbach, R. (1988).
Angiogenesis induction by CD-4
positive lymphocytes. Proc. Soc. Exp.
Biol. Med. 188, 440–443.
Kanazawa, S., Tsunoda, T., Onuma,
E., Majima, T., Kagiyama, M., and
Kikuchi, K. (2001). VEGF, basic-
FGF, and TGF-beta in Crohn’s dis-
ease and ulcerative colitis: a novel
mechanism of chronic intestinal
inﬂammation. Am. J. Gastroenterol.
96, 822–828.
Kang, D. H., Joly, A. H., Oh, S. W.,
Hugo, C., Kerjaschki, D., Gordon,
K. L., Mazzali, M., Jefferson, J. A.,
Hughes, J.,Madsen,K.M., Schreiner,
G. F., and Johnson, R. J. (2001a).
Impaired angiogenesis in the rem-
nant kidney model: I. Potential role
of vascular endothelial growth factor
and thrombospondin-1. J. Am. Soc.
Nephrol. 12, 1434–1447.
Kang, D. H., Hughes, J., Mazzali, M.,
Schreiner, G. F., and Johnson, R.
J. (2001b). Impaired angiogenesis
in the remnant kidney model: II.
Vascular endothelial growth factor
administration reduces renal ﬁbrosis
and stabilizes renal function. J. Am.
Soc. Nephrol. 12, 1448–1457.
Kang, D. H., Kanellis, J., Hugo, C.,
Truong, L., Anderson, S., Kerjaschki,
D., Schreiner, G. F., and Johnson, R.
J. (2002). Role of the microvascu-
lar endothelium in progressive renal
disease. J. Am. Soc. Nephrol. 13,
806–816.
Kim, I., Moon, S. O., Kim, S. H.,
Kim, H. J., Koh, Y. S., and Koh,
G. Y. (2001). Vascular endothelial
growth factor expression of intercel-
lular adhesion molecule 1 (ICAM-
1), vascular cell adhesion molecule 1
(VCAM-1), and E-selectin through
nuclear factor-kappa B activation in
endothelial cells. J. Biol. Chem. 276,
7614–7620.
Kim, Y. S., Hong, S. W., Choi, J. P., Shin,
T. S.,Moon,H.G.,Choi, E. J., Jeon, S.
G., Oh, S. Y., Gho, Y. S., Zhu, Z., and
Kim,Y. K. (2009). Vascular endothe-
lial growth factor is a key mediator
in the development of T cell prim-
ing and its polarization to type 1 and
type 17 T helper cells in the airways.
J. Immunol. 183, 5113–5120.
Klagsbrun, M., and D’Amore, P.
A. (1996). Vascular endothelial
growth factor and its receptors.
Cytokine Growth Factor Rev. 7,
259–270.
Koch, A. E., Harlow, L. A., Haines, G.
K., Amento, E. P., Unemori, E. N.,
Wong, W. L., Pope, R. M., and Fer-
rara, N. (1994). Vascular endothelial
growth factor. A cytokine modulat-
ing endothelial function in rheuma-
toid arthritis. J. Immunol. 152,
4149–4156.
Koch, A. E., Polverini, P. J., and
Leibovich, S. J. (1986). Induction
of neovascularization by activated
human monocytes. J. Leukoc. Biol.
39, 233–238.
Frontiers in Immunology | Immunological Tolerance April 2012 | Volume 3 | Article 54 | 10
Bruneau et al. The intragraft microenvironment
Kokudo, T., Suzuki, Y., Yoshimatsu,
Y., Yamazaki, T., Watabe, T., and
Miyazono, K. (2008). Snail is
required for TGFbeta-induced
endothelial-mesenchymal transi-
tion of embryonic stem cell-derived
endothelial cells. J. Cell. Sci. 121,
3317–3324.
Kreisel, D., Krupnick, A. S., Gelman,
A. E., Engels, F. H., Popma, S.
H., Krasinskas, A. M., Balsara, K.
R., Szeto, W. Y., Turka, L. A.,
and Rosengard, B. R. (2002). Non-
hematopoietic allograft cells directly
activate CD8+ T cells and trigger
acute rejection: an alternative mech-
anism of allorecognition. Nat. Med.
8, 233–239.
Laxmanan, S., Robertson, S. W., Wang,
E., Lau, J. S., Briscoe, D. M.,
and Mukhopadhyay, D. (2005).
Vascular endothelial growth factor
impairs the functional ability of den-
dritic cells through Id pathways.
Biochem. Biophys. Res. Commun.
334, 193–198.
Lee, C. G., Link, H., Baluk, P., Homer,
R. J., Chapoval, S., Bhandari, V.,
Kang, M. J., Cohn, L., Kim, Y.
K., McDonald, D. M., and Elias,
J. A. (2004). Vascular endothe-
lial growth factor (VEGF) induces
remodeling and enhances TH2-
mediated sensitization and inﬂam-
mation in the lung. Nat. Med. 10,
1095–1103.
Lee, S., Chen, T. T., Barber, C. L.,
Jordan, M. C., Murdock, J., Desai,
S., Ferrara, N., Nagy, A., Roos,
K. P., and Iruela-Arispe, M. L.
(2007). Autocrine VEGF signaling is
required for vascular homeostasis.
Cell 130, 691–703.
Leibovich, S. J., Polverini, P. J., Fong,
T. W., Harlow, L. A., and Koch,
A. E. (1994). Production of angio-
genic activity by human monocytes
requires an L-arginine/nitric oxide-
synthase-dependent effector mecha-
nism. Proc. Natl. Acad. Sci. U.S.A. 91,
4190–4194.
Leibovich, S. J., Polverini, P. J.,
Shepard, H. M., Wiseman, D.
M., Shively, V., and Nuseir, N.
(1987).Macrophage-induced angio-
genesis is mediated by tumour
necrosis factor-alpha. Nature 329,
630–632.
Leibovich, S. J., and Wiseman, D. M.
(1988). Macrophages, wound repair
and angiogenesis. Prog. Clin. Biol.
Res. 266, 131–145.
Lemstrom, K. B., Krebs, R., Nykanen, A.
I.,Tikkanen, J.M.,Sihvola,R.K.,Aal-
tola, E. M., Hayry, P. J.,Wood, J., Ali-
talo, K., Yla-Herttuala, S., and Kosk-
inen, P. K. (2002). Vascular endothe-
lial growth factor enhances cardiac
allograft arteriosclerosis. Circulation
105, 2524–2530.
Leonard, E. C., Friedrich, J. L., and
Basile, D. P. (2008). VEGF-121 pre-
serves renal microvessel structure
and ameliorates secondary renal dis-
ease following acute kidney injury.
Am. J. Physiol. Renal Physiol. 295,
F1648–F1657.
Leung, D. W., Cachianes, G., Kuang,
W. J., Goeddel, D. V., and Fer-
rara, N. (1989). Vascular endothe-
lial growth factor is a secreted
angiogenic mitogen. Science 246,
1306–1309.
Li, J., Qu, X., and Bertram, J.
F. (2009). Endothelial-myoﬁbroblast
transition contributes to the early
development of diabetic renal inter-
stitial ﬁbrosis in streptozotocin-
induced diabetic mice. Am. J. Pathol.
175, 1380–1388.
Libby,P., andPober, J. S. (2001).Chronic
rejection. Immunity 14, 387–397.
Majno, G. (1998). Chronic inﬂamma-
tion: links with angiogenesis and
wound healing. Am. J. Pathol. 153,
1035–1039.
Malmstrom, N. K., Kallio, E. A., Rin-
tala, J. M., Nykanen, A. I., Raisanen-
Sokolowski, A. K., Paavonen, T.,
Lemstrom, K. B., and Koskinen,
P. K. (2008). Vascular endothelial
growth factor in chronic rat allograft
nephropathy. Transpl. Immunol. 19,
136–144.
Mannon, R. B. (2006). Therapeutic
targets in the treatment of allo-
graft ﬁbrosis. Am. J. Transplant. 6,
867–875.
Markwald, R. R., Fitzharris, T. P., and
Smith, W. N. (1975). Structural
analysis of endocardial cytodifferen-
tiation. Dev. Biol. 42, 160–180.
Marumo, T., Schini-Kerth, V. B., and
Busse, R. (1999). Vascular endothe-
lial growth factor activates nuclear
factor-kappaB and induces mono-
cyte chemoattractant protein-1 in
bovine retinal endothelial cells. Dia-
betes 48, 1131–1137.
Matsumoto, T., and Mugishima, H.
(2006). Signal transduction via
vascular endothelial growth fac-
tor (VEGF) receptors and their
roles in atherogenesis. J. Atheroscler.
Thromb. 13, 130–135.
Mayer, G. (2011). Capillary rarefaction,
hypoxia, VEGF and angiogenesis in
chronic renal disease. Nephrol. Dial.
Transplant. 26, 1132–1137.
McDonald, D. M. (2001). Angiogene-
sis and remodeling of airway vas-
culature in chronic inﬂammation.
Am. J. Respir. Crit. Care Med. 164,
S39–S45.
Medici, D., Shore, E. M., Lounev, V. Y.,
Kaplan, F. S., Kalluri, R., and Olsen,
B. R. (2010). Conversion of vascu-
lar endothelial cells into multipo-
tent stem-like cells. Nat. Med. 16,
1400–1406.
Melder, R. J., Koenig, G. C., Witwer, B.
P., Safabakhsh, N., Munn, L. L., and
Jain, R. K. (1996). During angiogen-
esis, vascular endothelial growth fac-
tor andbasic ﬁbroblast growth factor
regulate natural killer cell adhesion
to tumor endothelium. Nat. Med. 2,
992–997.
Melter, M., Reinders, M. E., Sho, M.,
Pal, S., Geehan, C., Denton, M. D.,
Mukhopadhyay, D., and Briscoe, D.
M. (2000). Ligation of CD40 induces
the expression of vascular endothe-
lial growth factor by endothelial cells
andmonocytes andpromotes angio-
genesis in vivo.Blood 96, 3801–3808.
Miao, H. Q., and Klagsbrun, M. (2000).
Neuropilin is a mediator of angio-
genesis. Cancer Metastasis Rev. 19,
29–37.
Mizui, M., Kumanogoh, A., and
Kikutani, H. (2009). Immune
semaphorins: novel features of
neural guidance molecules. J. Clin.
Immunol. 1, 1–11.
Mor, F., Quintana, F. J., and Cohen, I. R.
(2004). Angiogenesis-inﬂammation
cross-talk: vascular endothelial
growth factor is secreted by acti-
vated T cells and induces Th1
polarization. J. Immunol. 172,
4618–4623.
Moulton, K. S., Melder, R. J., Dharnid-
harka, V. R., Hardin-Young, J., Jain,
R. K., and Briscoe, D. M. (1999).
Angiogenesis in the huPBL-SCID
model of human transplant rejec-
tion.Transplantation 67, 1626–1631.
Mukhopadhyay, D., Tsiokas, L., Zhou,
X. M., Foster, D., Brugge, J.
S., and Sukhatme, V. P. (1995).
Hypoxic induction of human vas-
cular endothelial growth factor
expression through c-Src activation.
Nature 375, 577–581.
Nakao, A., Choi, A. M., and Murase, N.
(2006). Protective effect of carbon
monoxide in transplantation. J. Cell.
Mol. Med. 10, 650–671.
Nykanen, A. I., Krebs, R., Saaristo,
A., Turunen, P., Alitalo, K., Yla-
Herttuala, S., Koskinen, P. K.,
and Lemstrom, K. B. (2003).
Angiopoietin-1 protects against the
development of cardiac allograft
arteriosclerosis. Circulation 107,
1308–1314.
Oberbauer, R., Segoloni, G., Campistol,
J. M., Kreis, H., Mota, A., Lawen, J.,
Russ, G., Grinyo, J. M., Stallone, G.,
Hartmann,A.,Pinto, J. R.,Chapman,
J., Burke, J. T., Brault, Y., and Ney-
lan, J. F. (2005). Early cyclosporine
withdrawal from a sirolimus-based
regimen results in better renal allo-
graft survival and renal function
at 48 months after transplantation.
Transpl. Int. 18, 22–28.
Osasan, S. A., de Freitas, D. G.,
Chang, J., Mengel, M., Halloran,
P. F., and Sis, B. (2011). Micro-
circulation endothelial cell cycling
is selectively increased in antibody-
mediated rejection of kidney trans-
plants, but not in other diseases. J.
Am. Soc. Nephrol. 22, 103A.
Peng, W., Chen, J., Jiang, Y., Shou, Z.,
Chen,Y., andWang,H. (2008).Acute
renal allograft rejection is associ-
ated with increased levels of vas-
cular endothelial growth factor in
the urine. Nephrology (Carlton) 13,
73–79.
Pilmore, H. L., Eris, J. M., Painter, D.
M., Bishop, G. A., and McCaughan,
G. W. (1999). Vascular endothelial
growth factor expression in human
chronic renal allograft rejection.
Transplantation 67, 929–933.
Pober, J. S., Orosz, C. G., Rose, M. L.,
and Savage, C. O. S. (1996). Can
graft endothelial cells initiate a host
anti-graft immune response? Trans-
plantation 61, 343–349.
Pober, J. S., and Sessa, W. C. (2007).
Evolving functions of endothelial
cells in inﬂammation. Nat. Rev.
Immunol. 7, 803–815.
Polverini, P. J. (1997). Role of the
macrophage in angiogenesis-
dependent diseases. EXS 79,
11–28.
Rabelink,T. J.,Wijewickrama,D.C., and
de Koning, E. J. (2007). Peritubular
endothelium: the Achilles heel of the
kidney? Kidney Int. 72, 926–930.
Reinders, M. E., and Briscoe, D. M.
(2002). Angiogenesis and allograft
rejection. Graft 5, 96–101.
Reinders, M. E., Rabelink, T. J., and
Briscoe, D. M. (2006). Angiogen-
esis and endothelial cell repair in
renal disease and allograft rejec-
tion. J. Am. Soc. Nephrol. 17,
932–942.
Reinders, M. E., Sho, M., Izawa, A.,
Wang, P., Mukhopadhyay, D., Koss,
K. E., Geehan, C. S., Luster, A. D.,
Sayegh, M. H., and Briscoe, D. M.
(2003a). Proinﬂammatory functions
of vascular endothelial growth factor
in alloimmunity. J. Clin. Invest. 112,
1655–1665.
Reinders, M. E., Fang, J. C., Wong,
W., Ganz, P., and Briscoe, D. M.
(2003b). Expression patterns of vas-
cular endothelial growth factor in
human cardiac allografts: associa-
tion with rejection. Transplantation
76, 224–230.
Romeo, P. H., Lemarchandel, V., and
Tordjman, R. (2002). Neuropilin-1
www.frontiersin.org April 2012 | Volume 3 | Article 54 | 11
Bruneau et al. The intragraft microenvironment
in the immune system. Adv. Exp.
Med. Biol. 515, 49–54.
Sarris, M., Andersen, K. G., Randow,
F., Mayr, L., and Betz, A. G. (2008).
Neuropilin-1 expression on regula-
tory T cells enhances their inter-
actions with dendritic cells during
antigen recognition. Immunity 28,
402–413.
Schena, F. P., Pascoe, M. D., Alberu,
J., del Carmen Rial, M., Oberbauer,
R., Brennan, D. C., Campistol, J.
M., Racusen, L., Polinsky, M. S.,
Goldberg-Alberts, R., Li, H., Scarola,
J., and Neylan, J. F. (2009). Con-
version from calcineurin inhibitors
to sirolimus maintenance therapy in
renal allograft recipients: 24-month
efﬁcacy and safety results from the
CONVERT trial.Transplantation 87,
233–242.
Schor, A. M., Canﬁeld, A. E., Sut-
ton, A. B., Arciniegas, E., and
Allen, T. D. (1995). Pericyte differ-
entiation. Clin. Orthop. Relat. Res.
81–91.
Shahbazi, M., Fryer, A. A., Pravica,
V., Brogan, I. J., Ramsay, H. M.,
Hutchinson, I. V., and Harden, P. N.
(2002). Vascular endothelial growth
factor gene polymorphisms are asso-
ciated with acute renal allograft
rejection. J. Am. Soc. Nephrol. 13,
260–264.
Shalaby, F., Rossant, J., Yamaguchi, T.
P., Gertsenstein, M., Wu, X. F.,
Breitman, M. L., and Schuh, A.
C. (1995). Failure of blood-island
formation and vasculogenesis in
Flk-1-deﬁcient mice. Nature 376,
62–66.
Sharma, V. K., Bologa, R. M., Xu, G.
P., Li, B., Mouradian, J., Wang, J.,
Serur, D., Rao, V., and Suthanthi-
ran, M. (1996). Intragraft TGF-
beta 1 mRNA: a correlate of inter-
stitial ﬁbrosis and chronic allo-
graft nephropathy. Kidney Int. 49,
1297–1303.
Shin, J. Y., Yoon, I. H., Kim, J.
S., Kim, B., and Park, C. G.
(2009). Vascular endothelial growth
factor-induced chemotaxis and IL-
10 from T cells. Cell. Immunol. 256,
72–78.
Sho, M., Akashi, S., Kanehiro, H.,
Hamada, K., Kashizuka, H., Ikeda,
N., Nomi, T., Kuzumoto, Y., Tsu-
rui, Y., Yoshiji, H., Wu, Y., Hicklin,
D. J., Briscoe, D. M., and Nakajima,
Y. (2005). Function of the vascular
endothelial growth factor receptors
Flt-1 and Flk-1/KDR in the alloim-
mune response in vivo. Transplanta-
tion 80, 717–722.
Shweiki, D., Itin, A., Soffer, D.,
and Keshet, E. (1992). Vascular
endothelial growth factor induced
by hypoxia may mediate hypoxia-
initiated angiogenesis. Nature 359,
843–845.
Sidky, Y. A., and Auerbach, R. (1975).
Lymphocyte-induced angiogenesis:
a quantitative and sensitive assay of
the graft-vs.-host reaction. J. Exp.
Med. 141, 1084–1100.
Sis, B., and Halloran, P. F. (2010).
Endothelial transcripts uncover a
previously unknown phenotype:
C4d-negative antibody-mediated
rejection. Curr. Opin. Organ
Transplant. 15, 42–48.
Sis, B., Jhangri, G. S., Bunnag, S.,
Allanach, K., Kaplan, B., and Hal-
loran, P. F. (2009). Endothelial
gene expression in kidney trans-
plants with alloantibody indicates
antibody-mediated damage despite
lack of C4d staining. Am. J. Trans-
plant. 9, 2312–2323.
Steegh, F. M., Gelens, M. A., Nieman, F.
H., van Hooff, J. P., Cleutjens, J. P.,
van Suylen, R. J., Daemen, M. J., van
Heurn, E. L., Christiaans,M. H., and
Peutz-Kootstra, C. J. (2011). Early
loss of peritubular capillaries after
kidney transplantation. J. Am. Soc.
Nephrol. 22, 1024–1029.
Strieter, R. M., Kunkel, S. L., Arenberg,
D. A., Burdick, M. D., and Polverini,
P. J. (1995a). Interferon gamma-
inducible protein 10 (IP-10), amem-
ber of the C-X-C chemokine fam-
ily, is an inhibitor of angiogene-
sis. Biochem. Biophys. Res. Commun.
210, 51–57.
Strieter, R. M., Polverini, P. J., Arenberg,
D. A., and Kunkel, S. L. (1995b).
The role of CXC chemokines as
regulators of angiogenesis. Shock 4,
155–160.
Suzuki, H., Onishi, H., Wada, J.,
Yamasaki,A.,Tanaka,H.,Nakano,K.,
Morisaki, T., and Katano, M. (2010).
VEGFR2 is selectively expressed by
FOXP3high CD4+ Treg. Eur. J.
Immunol. 40, 197–203.
Suzuki, K., Kumanogoh, A., and
Kikutani, H. (2008). Semaphorins
and their receptors in immune
cell interactions. Nat. Immunol. 9,
17–23.
Takahashi, H., and Shibuya, M. (2005).
The vascular endothelial growth fac-
tor (VEGF)/VEGF receptor system
and its role under physiological and
pathological conditions. Clin. Sci.
109, 227–241.
Tanaka,H., Sukhova,G. K., and Libby, P.
(1994). Interaction of the allogeneic
state and hypercholesterolemia in
arterial lesion formation in exper-
imental cardiac allografts. Arte-
rioscler. Thromb. 14, 734–745.
Tischer, E., Mitchell, R., Hartman, T.,
Silva,M.,Gospodarowicz,D.,Fiddes,
J. C., and Abraham, J. A. (1991). The
human gene for vascular endothe-
lial growth factor. Multiple protein
forms are encoded through alterna-
tive exon splicing. J. Biol. Chem. 266,
11947–11954.
Tordjman, R., Lepelletier, Y.,
Lemarchandel, V., Cambot, M.,
Gaulard, P., Hermine, O., and
Romeo, P. H. (2002). A neuronal
receptor, neuropilin-1, is essential
for the initiation of the primary
immune response. Nat. Immunol. 3,
477–482.
Torry, R. J., Labarrere, C. A., Torry,
D. S., Holt, V. J., and Faulk, W. P.
(1995). Vascular endothelial growth
factor expression in transplanted
human hearts. Transplantation 60,
1451–1457.
Valujskikh, A., and Heeger, P. S. (2003).
Emerging roles of endothelial cells
in transplant rejection. Curr. Opin.
Immunol. 15, 493–498.
Vos, I. H., and Briscoe, D. M.
(2002). Endothelial injury: cause
and effect of alloimmune inﬂamma-
tion. Transpl. Infect. Dis. 4, 152–159.
Walsh, D. A., and Pearson, C. I. (2001).
Angiogenesis in the pathogenesis of
inﬂammatory joint and lung dis-
eases. Arthritis Res. 3, 147–153.
Wang, L., Zeng, H., Wang, P., Soker,
S., and Mukhopadhyay, D. (2003).
Neuropilin-1-mediated vascu-
lar permeability factor/vascular
endothelial growth factor-
dependent endothelial cell
migration. J. Biol. Chem. 278,
48848–48860.
Watanabe, H., Mamelak, A. J.,Wang, B.,
Howell, B. G., Freed, I., Esche, C.,
Nakayama, M., Nagasaki, G., Hick-
lin, D. J., Kerbel, R. S., and Sauder,
D.N. (2004).Anti-vascular endothe-
lial growth factor receptor-2 (Flk-
1/KDR) antibody suppresses contact
hypersensitivity. Exp. Dermatol. 13,
671–681.
Watanabe, H., Mamelak, A. J., Weiss,
E., Wang, B., Freed, I., Brice, A.
K., Wachtman, L., Gabrielson, K.
L., Yokota, N., Hicklin, D. J., Ker-
bel, R. S., Haas, M., and Sauder, D.
N. (2005). Anti-vascular endothe-
lial growth factor receptor-2 anti-
body accelerates renal disease in the
NZB/W F1 murine systemic lupus
erythematosus model. Clin. Cancer
Res. 11, 407–409.
Wiseman, D. M., Polverini, P. J.,
Kamp, D. W., and Leibovich, S. J.
(1988). Transforming growth factor-
beta (TGF beta) is chemotactic for
human monocytes and induces their
expression of angiogenic activity.
Biochem. Biophys. Res. Commun.
157, 793–800.
Woywodt, A., Schroeder, M., Gwinner,
W., Mengel, M., Jaeger, M., Schwarz,
A., Haller, H., and Haubitz, M.
(2003). Elevated numbers of circu-
lating endothelial cells in renal trans-
plant recipients. Transplantation 76,
1–4.
Zeisberg, E. M., Tarnavski, O., Zeisberg,
M., Dorfman, A. L., McMullen, J. R.,
Gustafsson,E.,Chandraker,A.,Yuan,
X., Pu,W. T., Roberts, A. B., Neilson,
E. G., Sayegh, M. H., Izumo, S., and
Kalluri, R. (2007a). Endothelial-to-
mesenchymal transition contributes
to cardiac ﬁbrosis. Nat. Med. 13,
952–961.
Zeisberg, E. M., Potenta, S., Xie, L., Zeis-
berg, M., and Kalluri, R. (2007b).
Discovery of endothelial to mes-
enchymal transition as a source
for carcinoma-associated ﬁbrob-
lasts. Cancer Res. 67, 10123–10128.
Zeng, H., Dvorak, H. F., and
Mukhopadhyay, D. (2001). Vascular
permeability factor (VPF)/vascular
endothelial growth factor (VEGF)
receptor-1 down-modulates VPF/
VEGF receptor-2-mediated endo-
thelial cell proliferation, but not
migration, through phosphatidyli-
nositol 3-kinase-dependent path-
ways. J. Biol. Chem. 276,
26969–26979.
Zeng,H., Zhao, D., and Mukhopadhyay,
D. (2002). Flt-1-mediated down-
regulation of endothelial cell pro-
liferation through pertussis toxin-
sensitive G proteins, beta gamma
subunits, small GTPase CDC42, and
partly by Rac-1. J. Biol. Chem. 277,
4003–4009.
Zhang, J., Silva,T.,Yarovinsky,T.,Manes,
T. D., Tavakoli, S., Nie, L., Tellides,
G., Pober, J. S., Bender, J. R., and
Sadeghi,M. M. (2010). VEGF block-
ade inhibits lymphocyte recruitment
and ameliorates immune-mediated
vascular remodeling. Circ. Res. 107,
408–417.
Zhang, X., and Reed, E. F. (2009). Effect
of antibodies on endothelium. Am.
J. Transplant. 9, 2459–2465.
Zhao, Q., Egashira, K., Inoue, S.,
Usui, M., Kitamoto, S., Ni, W.,
Ishibashi, M., Hiasa Ki, K., Ichiki,
T., Shibuya, M., and Takeshita,
A. (2002). Vascular endothelial
growth factor is necessary in
the development of arterioscle-
rosis by recruiting/activating
monocytes in a rat model of
long-term inhibition of nitric
oxide synthesis. Circulation 105,
1110–1115.
Ziogas,A. C., Gavalas,N. G., Tsiatas,M.,
Tsitsilonis, O., Politi, E., Terpos, E.,
Rodolakis,A.,Vlahos,G.,Thomakos,
N., Haidopoulos, D., Antsaklis, A.,
Frontiers in Immunology | Immunological Tolerance April 2012 | Volume 3 | Article 54 | 12
Bruneau et al. The intragraft microenvironment
Dimopoulos, M. A., and Bamias,
A. (2011). VEGF directly suppresses
activation of T cells from ovarian
cancer patients and healthy individ-
uals via VEGF receptor type 2. Int. J.
Cancer 130, 857–864.
Conﬂict of Interest Statement: David
M. Briscoe has received research
funding from the Roche Organ
Transplantation Research Foundation,
Astellas, Wyeth, and Pﬁzer Pharmaceu-
ticals, and is an inventor on US Patent
#6218361. He has given seminars at
educational CME-approved confer-
ences and grand rounds sponsored by
pharmaceutical companies. All other
authors do not have any disclosures.
Received: 17 January 2012; accepted: 02
March 2012; published online: 02 April
2012.
Citation: Bruneau S, Woda CB, Daly
KP,Boneschansker L, Jain NG,Kochupu-
rakkal N, Contreras AG, Seto T and
Briscoe DM (2012) Key features of the
intragraft microenvironment that deter-
mine long-term survival following trans-
plantation. Front. Immun. 3:54. doi:
10.3389/ﬁmmu.2012.00054
This article was submitted to Frontiers in
Immunological Tolerance, a specialty of
Frontiers in Immunology.
Copyright © 2012 Bruneau, Woda,
Daly, Boneschansker, Jain, Kochupu-
rakkal, Contreras, Seto and Briscoe.
This is an open-access article distrib-
uted under the terms of the Cre-
ative Commons Attribution Non Com-
mercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided
the original authors and source are
credited.
www.frontiersin.org April 2012 | Volume 3 | Article 54 | 13
